These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 9305607

  • 21. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
    Michieli M, Damiani D, Michelutti A, Candoni A, Masolini P, Scaggiante B, Quadrifoglio F, Baccarani M.
    Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
    Kim WY, Benet LZ.
    Pharm Res; 2004 Jul; 21(7):1284-93. PubMed ID: 15290871
    [Abstract] [Full Text] [Related]

  • 25. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML).
    Marie JP, Helou C, Thevenin D, Delmer A, Zittoun R.
    Exp Hematol; 1992 Jun; 20(5):565-8. PubMed ID: 1350249
    [Abstract] [Full Text] [Related]

  • 26. Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.
    Yang JY, Luo HY, Lin QY, Liu ZM, Yan LN, Lin P, Zhang J, Lei S.
    World J Gastroenterol; 2002 Aug; 8(4):644-9. PubMed ID: 12174371
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JP, Eekman CA, Kuiper CM, Feller N, van Heijningen TH, Klumper E, Pieters R.
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [Abstract] [Full Text] [Related]

  • 31. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O.
    Clin Cancer Res; 2004 Dec 01; 10(23):7896-902. PubMed ID: 15585622
    [Abstract] [Full Text] [Related]

  • 32. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
    Hargrave RM, Davey MW, Davey RA, Kidman AD.
    Anticancer Drugs; 1995 Jun 01; 6(3):432-7. PubMed ID: 7670142
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, Meletis J, Rombos Y, Sagriotis A, Symeonidis A, Tiniakou M, Zoumbos N, Yataganas X.
    Leuk Res; 2002 Feb 01; 26(2):143-54. PubMed ID: 11755464
    [Abstract] [Full Text] [Related]

  • 34. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD, Rao VV, Crankshaw CL, Dahlheimer J, Piwnica-Worms D.
    Biochemistry; 1997 Nov 18; 36(46):14218-27. PubMed ID: 9369495
    [Abstract] [Full Text] [Related]

  • 35. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
    Wang YH, Imai Y, Shiseki M, Tanaka J, Motoji T.
    Leuk Res; 2018 Apr 18; 67():99-108. PubMed ID: 29482174
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris.
    Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin JL, de Cremoux P, Delvincourt C, Demur C, Drenou B, Fenneteau O, Feuillard J, Garnier-Suillerot A, Genne P, Gorisse MC, Gosselin P, Jouault H, Lacave R, Robert J.
    Leukemia; 1997 Jul 18; 11(7):1086-94. PubMed ID: 9204996
    [Abstract] [Full Text] [Related]

  • 38. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P.
    Cancer Res; 2001 Jan 15; 61(2):749-58. PubMed ID: 11212278
    [Abstract] [Full Text] [Related]

  • 39. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
    Grey M, Borg AG, Wood P, Burgess R, Fisher A, Yin JA.
    Leuk Res; 1997 Sep 15; 21(9):867-74. PubMed ID: 9393602
    [Abstract] [Full Text] [Related]

  • 40. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
    Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D.
    Int J Cancer; 1990 Feb 15; 45(2):263-8. PubMed ID: 1968051
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.